

Sareum Holdings PLC

("Sareum" or the "Company")

Appointment of Joint Corporate Broker

Cambridge, UK, 30 October 2025- Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next-generation kinase inhibitors for autoimmune disease and cancer, is pleased to announce the appointment of Singer Capital Markets as Joint Corporate Broker with immediate effect. Strand Hanson Limited remains as the Company's Nominated Adviser, and Oberon Capital as Joint Corporate Broker.

- Ends -

For further information:

Sareum Holdings plc

Stephen Parker, Executive Chairman

01223 497700

ir@sareum.co.uk

Strand Hanson Limited (Nominated Adviser)

James Dance / James Bellman

020 7409 3494

Singer Capital Markets (Joint Corporate Broker)

Phil Davies

020 7496 3000

Oberon Capital (Joint Corporate Broker)

Mike Seabrook / Nick Lovering

020 3179 5300

ICR Healthcare (Financial PR)

Jessica Hodgson / Davide Salvi

020 3709 5700

About Sareum

Sareum (AIM: SAR) is a biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer.

The Company is focused on developing next generation small molecules which modify the activity of the JAK kinase family and have best-in-class potential. Its lead candidate, SDC-1801, simultaneously inhibits TYK2 and JAK1. SDC-1801 is a potential treatment for a range of autoimmune diseases, with a planned initial focus on psoriasis.

Sareum is also developing SDC-1802, a TYK2/JAK1 inhibitor with a potential application for cancer immunotherapy, and has recently initiated a preclinical programme to develop TYK2/JAK1 inhibitors for neuroinflammatory diseases such as multiple sclerosis and Parkinson's disease.

The Company is the license holder for SRA737, a clinical-stage Checkpoint kinase 1 inhibitor that targets cancer cell replication and DNA damage repair mechanisms.

Sareum Holdings plc is based in Cambridge, UK, and is quoted on the AIM market of the London Stock Exchange, trading under the ticker SAR. For further information, please visit the Company's website at www.sareum.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

APPBCBDGDDDDGUC